Journal of the neurological sciences
-
Randomized Controlled Trial Multicenter Study
Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment.
To evaluate peripheral nerve safety and clinical efficacy of tanezumab in patients with painful osteoarthritis. ⋯ Tanezumab has a modulating effect on pain, does not appear to increase neurological safety signals, and offers a potentially promising, novel approach in treatment of pain.
-
Randomized Controlled Trial Comparative Study
An open labeled randomized controlled trial of pregabalin versus amitriptyline in chronic low backache.
There is no head on comparison of amitriptyline (AMT) and pregabalin (PG) in relieving pain and disability in chronic low backache (CLBA). This randomized controlled trial reports the efficacy and safety of AMT and PG in CLBA. ⋯ AMT and PG are effective in CLBA but AMT reduced pain and disability significantly compared to PG.
-
Randomized Controlled Trial Multicenter Study
Development of a short form of Stroke-Specific Quality of Life Scale for patients after aneurysmal subarachnoid hemorrhage.
The identification of aneurysmal subarachnoid hemorrhage (aSAH) patients with a decrease in health-related quality of life (HRQOL) is challenging. Stroke-Specific Quality of Life (SS-QOL) Scale is one of the commonest disease-specific quality of life measures initially developed and validated for ischemic stroke patients. A disadvantage is subject burden and a short form is more practical to use in clinical and research setting. ⋯ The 12-item Chinese version of SSQOL-a has a satisfactory internal consistency and criterion validity for SAH patients at 12 month assessments.
-
Randomized Controlled Trial
Neuropsychological rehabilitation has beneficial effects on perceived cognitive deficits in multiple sclerosis during nine-month follow-up.
Systematic reviews have indicated a low level of evidence for the positive effects of neuropsychological and cognitive rehabilitation in multiple sclerosis (MS). How permanent the positive effects are, is unknown. ⋯ The beneficial effects of strategy-oriented neuropsychological rehabilitation on perceived cognitive deficits in MS may be maintained for at least one year after the beginning of the intervention.
-
Randomized Controlled Trial
Erythropoietin prevents delayed hemodynamic dysfunction after subarachnoid hemorrhage in a randomized controlled experimental setting.
Erythropoietin (EPO) was proven as a promising approach for experimental subarachnoid hemorrhage (SAH). Clinical data are, however, inconclusive so far. A detailed characterization of specific EPO effects could facilitate the design of trials. The aim of the present investigation was, therefore, to characterize these effects on prevention of delayed proximal cerebral vasospasm (CVS), impaired microcirculation and cerebral blood flow (CBF) after experimental SAH. ⋯ The present data suggest that an EPO application in a timely distance to the SAH is sufficient to prevent delayed proximal CVS, but that the doses were insufficient to improve microcirculation or to be directly neuroprotective.